Janja Marc is also active in professional field. In 2002, she obtained her specialization in laboratory medicine (European Specialist in Laboratory Medicine – EuSpLM) at the Ministry of Health and so fulfilled the conditions to be a head of laboratory. Since 2004, she is a head of Laboratory for molecular diagnostics (LMD), which is professionally independent part of Faculty of Pharmacy in Ljubljana and has a license of Ministry of Health of Republic of Slovenia to perform analysis in the field of medical biochemistry (MZ št. 0600114/20095,26.10.2009). LMD has implemented quality assurance measures and is regularly involved in international independantd quality control supervision. In LMB, 19 clinical genetic tests are available, intended for differential diagnostics and personalized medicine of chronic and inborn metabolic disorders and pharmacogenetics. These genetic tests are available for doctors, patients and research institutions. LMD performs also a part of a program for specialization in medical biochemistry, thus connecting professional, scientific and educational fields. Through LMD and performance of laboratory diagnostic tests, a translation of scientific results directly to patients was made possible.
D.07 Presiding over a centre/laboratory
COBISS.SI-ID: 3715441Professional societies for traumatology, osteology and physiatrics have written the recommendations for management of acute hip fracture in the elderly in Slovenia, which include acute surgical treatment, medical rehabilitation and secondary prevention with treatment of osteoporosis. The recommendations were adopted by the Board for Surgery at the Ministry of Health of the Republic of Slovenia in June and September 2011.
F.22 Improvement to existing health/diagnostic methods/procedures
COBISS.SI-ID: 1536105Osteoporotic fractures are major cause of disability and death. If we want to effectively prevent them, we should treat individuals at high risk of fracture. Primarily, we treat patients after osteoporotic vertebral or hip fracture, where it is required only to exclude secondary causes of osteoporosis prior to initiating treatment. For other women after menopause, the risk of fracture could be assessed using clinical factors, which are entered into the computer-driven FRAX algorithm. The measurement of bone mineral density could also be used, but we have to take into account the age and sex of subjects when interpreting the result. Treatment of osteoporosis requires a healthy lifestyle without smoking and excessive alcohol intake. The diet should be rich in calcium and protein. Regular physical exercise has positive effects on the bone as well as on the muscles and fall prevention. The addition of vitamin D is always recommended. Drugs have proven efficacy against osteoporotic fractures. We can choose between several inhibitors of bone resorption, such as estrogens, biophosphonates, raloxifene and denosumab. Teriparatide is an anabolic drug that promotes bone formation, while strontium ranelate has a beneficial effect on both processes of bone turnover.
F.22 Improvement to existing health/diagnostic methods/procedures
COBISS.SI-ID: 4635711